Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPME1 | Q9Y570 | 5/20 | 0.55 |
| ▸ | APEH | P13798 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28139909 | 0.76 | PPME1 (0.51) | PPME1APEHHTR6MEN1ALDH1A1 | |
| SCHEMBL16530109 | 0.76 | HTR6 (0.39) | PPME1APEHHTR6ALDH1A1LMNA | |
| SCHEMBL15358101 | 0.73 | RAPGEF4 (0.36) | PPME1APEHALDH1A1LMNAHTT | |
| SCHEMBL3796218 | 0.72 | RAPGEF4 (0.41) | PPME1APEHHTR6MEN1ALDH1A1 | |
| SCHEMBL1599343 | 0.72 | HTR6 (0.50) | PPME1APEHHTR6MEN1ALDH1A1 | |
| SCHEMBL1599348 | 0.72 | HTR6 (0.50) | PPME1APEHHTR6MEN1ALDH1A1 | |
| SCHEMBL14760380 | 0.72 | HTR6 (0.50) | PPME1APEHHTR6MEN1ALDH1A1 | |
| SCHEMBL28189646 | 0.72 | HTR6 (0.50) | PPME1APEHHTR6MEN1ALDH1A1 | |
| SCHEMBL29954478 | 0.71 | PPME1 (0.48) | PPME1APEHHTR6MEN1ALDH1A1 | |
| SCHEMBL1616366 | 0.69 | PPME1 (0.60) | PPME1APEHHTR6MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398141-B2 | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) | 2025-08-26 | — | — | US | disclosed |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398141-B2 | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine | JAK1, JAK2, JAK3 | PPME1 315/4885APEH 2595/4885HTR6 4345/4885 |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | JAK1, JAK2, JAK3 | PPME1 315/4885APEH 2595/4885HTR6 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.